A review of the latest executive moves in the pharma industry over the past several months.

With $120 million in backing, Human Immunology Biosciences (HI-Bio) launched two assets licensed from MorphoSys AG aimed at severe immune-mediated diseases.

Merck veteran Fiona H. Marshall has been tapped as president of the Novartis Institutes for BioMedical Research (NIBR). She takes over from Jay Bradner, who will leave the company effective Oct. 31.